Table 6.
Effect of number of pre-switch antipsychotics used during switch on incidence of adverse events over the full treatment period (26 weeks)
| Asenapine (5–10 mg twice daily) | Olanzapine (5–20 mg once daily) | |||||
|---|---|---|---|---|---|---|
| Patients (n) | 329 | 107 | 23 | 335 | 93 | 19 |
| Pretreatment antipsychotics (n) | 1 | 2 | 3 | 1 | 2 | 3 |
| Total (%) | 76.3 | 79.4 | 73.9 | 72.2 | 83.9 | 84.2 |
| Somnolence (%) | 14.0 | 14.0 | 8.7 | 14.6 | 21.5 | 0 |
| Sedation (%) | 5.5 | 2.8 | 4.3 | 6.9 | 3.2 | 0 |
| Insomnia (%) | 14.9 | 24.3 | 8.7 | 9.9 | 15.1 | 15.8 |
| Weight increase (%) | 7.6 | 5.6 | 0 | 20.9 | 26.9 | 5.3 |
| Weight decrease (%) | 3.6 | 5.6 | 8.7 | 0.6 | 1.1 | 5.3 |
| Headache (%) | 14.9 | 11.2 | 4.3 | 11.0 | 8.6 | 0 |
| Nausea (%) | 7.0 | 8.4 | 0 | 3.0 | 7.5 | 0 |
| Anxiety (%) | 8.5 | 15.0 | 8.7 | 7.2 | 7.5 | 15.8 |
| Agitation (%) | 4.3 | 6.5 | 4.3 | 0 | 6.5 | 0 |